The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Induced Pluripotent Stem Cells (iPSCs) Market Research Report 2025
Synopsis
The global market for Induced Pluripotent Stem Cells (iPSCs) was valued at US$ 128 million in the year 2024 and is projected to reach a revised size of US$ 285 million by 2031, growing at a CAGR of 12.3% during the forecast period.
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.
United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.
The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.
This report aims to provide a comprehensive presentation of the global market for Induced Pluripotent Stem Cells (iPSCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Induced Pluripotent Stem Cells (iPSCs).
The Induced Pluripotent Stem Cells (iPSCs) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Induced Pluripotent Stem Cells (iPSCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Induced Pluripotent Stem Cells (iPSCs) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL
Segment by Type
Human iPSCs
Mouse iPSCs
Segment by Application
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Induced Pluripotent Stem Cells (iPSCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global market for Induced Pluripotent Stem Cells (iPSCs) was valued at US$ 128 million in the year 2024 and is projected to reach a revised size of US$ 285 million by 2031, growing at a CAGR of 12.3% during the forecast period.
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.
United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.
The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.
This report aims to provide a comprehensive presentation of the global market for Induced Pluripotent Stem Cells (iPSCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Induced Pluripotent Stem Cells (iPSCs).
The Induced Pluripotent Stem Cells (iPSCs) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Induced Pluripotent Stem Cells (iPSCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Induced Pluripotent Stem Cells (iPSCs) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology
ReproCELL
Segment by Type
Human iPSCs
Mouse iPSCs
Segment by Application
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Induced Pluripotent Stem Cells (iPSCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Human iPSCs
1.2.3 Mouse iPSCs
1.3 Market by Application
1.3.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Academic Research
1.3.3 Drug Development and Discovery
1.3.4 Toxicity Screening
1.3.5 Regenerative Medicine
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Perspective (2020-2031)
2.2 Global Induced Pluripotent Stem Cells (iPSCs) Growth Trends by Region
2.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Induced Pluripotent Stem Cells (iPSCs) Historic Market Size by Region (2020-2025)
2.2.3 Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Region (2026-2031)
2.3 Induced Pluripotent Stem Cells (iPSCs) Market Dynamics
2.3.1 Induced Pluripotent Stem Cells (iPSCs) Industry Trends
2.3.2 Induced Pluripotent Stem Cells (iPSCs) Market Drivers
2.3.3 Induced Pluripotent Stem Cells (iPSCs) Market Challenges
2.3.4 Induced Pluripotent Stem Cells (iPSCs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Induced Pluripotent Stem Cells (iPSCs) Players by Revenue
3.1.1 Global Top Induced Pluripotent Stem Cells (iPSCs) Players by Revenue (2020-2025)
3.1.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Players (2020-2025)
3.2 Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Induced Pluripotent Stem Cells (iPSCs) Revenue
3.4 Global Induced Pluripotent Stem Cells (iPSCs) Market Concentration Ratio
3.4.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Induced Pluripotent Stem Cells (iPSCs) Revenue in 2024
3.5 Global Key Players of Induced Pluripotent Stem Cells (iPSCs) Head office and Area Served
3.6 Global Key Players of Induced Pluripotent Stem Cells (iPSCs), Product and Application
3.7 Global Key Players of Induced Pluripotent Stem Cells (iPSCs), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Type
4.1 Global Induced Pluripotent Stem Cells (iPSCs) Historic Market Size by Type (2020-2025)
4.2 Global Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Type (2026-2031)
5 Induced Pluripotent Stem Cells (iPSCs) Breakdown Data by Application
5.1 Global Induced Pluripotent Stem Cells (iPSCs) Historic Market Size by Application (2020-2025)
5.2 Global Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Induced Pluripotent Stem Cells (iPSCs) Market Size (2020-2031)
6.2 North America Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2020-2025)
6.4 North America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Induced Pluripotent Stem Cells (iPSCs) Market Size (2020-2031)
7.2 Europe Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2020-2025)
7.4 Europe Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size (2020-2031)
8.2 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2020-2025)
8.4 Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size (2020-2031)
9.2 Latin America Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2020-2025)
9.4 Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size (2020-2031)
10.2 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2020-2025)
10.4 Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Fujifilm Holding Corporation (CDI)
11.1.1 Fujifilm Holding Corporation (CDI) Company Details
11.1.2 Fujifilm Holding Corporation (CDI) Business Overview
11.1.3 Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Introduction
11.1.4 Fujifilm Holding Corporation (CDI) Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
11.1.5 Fujifilm Holding Corporation (CDI) Recent Development
11.2 Ncardia
11.2.1 Ncardia Company Details
11.2.2 Ncardia Business Overview
11.2.3 Ncardia Induced Pluripotent Stem Cells (iPSCs) Introduction
11.2.4 Ncardia Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
11.2.5 Ncardia Recent Development
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Details
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
11.3.5 Sumitomo Dainippon Pharma Recent Development
11.4 Astellas Pharma Inc
11.4.1 Astellas Pharma Inc Company Details
11.4.2 Astellas Pharma Inc Business Overview
11.4.3 Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Introduction
11.4.4 Astellas Pharma Inc Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
11.4.5 Astellas Pharma Inc Recent Development
11.5 Fate Therapeutics, Inc
11.5.1 Fate Therapeutics, Inc Company Details
11.5.2 Fate Therapeutics, Inc Business Overview
11.5.3 Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Introduction
11.5.4 Fate Therapeutics, Inc Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
11.5.5 Fate Therapeutics, Inc Recent Development
11.6 Pluricell Biotech
11.6.1 Pluricell Biotech Company Details
11.6.2 Pluricell Biotech Business Overview
11.6.3 Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Introduction
11.6.4 Pluricell Biotech Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
11.6.5 Pluricell Biotech Recent Development
11.7 Cell Inspire Biotechnology
11.7.1 Cell Inspire Biotechnology Company Details
11.7.2 Cell Inspire Biotechnology Business Overview
11.7.3 Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Introduction
11.7.4 Cell Inspire Biotechnology Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
11.7.5 Cell Inspire Biotechnology Recent Development
11.8 ReproCELL
11.8.1 ReproCELL Company Details
11.8.2 ReproCELL Business Overview
11.8.3 ReproCELL Induced Pluripotent Stem Cells (iPSCs) Introduction
11.8.4 ReproCELL Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
11.8.5 ReproCELL Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Human iPSCs
Table 3. Key Players of Mouse iPSCs
Table 4. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Region (2020-2025)
Table 8. Global Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Region (2026-2031)
Table 10. Induced Pluripotent Stem Cells (iPSCs) Market Trends
Table 11. Induced Pluripotent Stem Cells (iPSCs) Market Drivers
Table 12. Induced Pluripotent Stem Cells (iPSCs) Market Challenges
Table 13. Induced Pluripotent Stem Cells (iPSCs) Market Restraints
Table 14. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Players (2020-2025)
Table 16. Global Top Induced Pluripotent Stem Cells (iPSCs) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Induced Pluripotent Stem Cells (iPSCs) as of 2024)
Table 17. Ranking of Global Top Induced Pluripotent Stem Cells (iPSCs) Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Induced Pluripotent Stem Cells (iPSCs) Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Induced Pluripotent Stem Cells (iPSCs), Headquarters and Area Served
Table 20. Global Key Players of Induced Pluripotent Stem Cells (iPSCs), Product and Application
Table 21. Global Key Players of Induced Pluripotent Stem Cells (iPSCs), Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Type (2020-2025)
Table 25. Global Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Type (2026-2031)
Table 27. Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Application (2020-2025)
Table 29. Global Induced Pluripotent Stem Cells (iPSCs) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Application (2026-2031)
Table 31. North America Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size by Country (2026-2031) & (US$ Million)
Table 46. Fujifilm Holding Corporation (CDI) Company Details
Table 47. Fujifilm Holding Corporation (CDI) Business Overview
Table 48. Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Product
Table 49. Fujifilm Holding Corporation (CDI) Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025) & (US$ Million)
Table 50. Fujifilm Holding Corporation (CDI) Recent Development
Table 51. Ncardia Company Details
Table 52. Ncardia Business Overview
Table 53. Ncardia Induced Pluripotent Stem Cells (iPSCs) Product
Table 54. Ncardia Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025) & (US$ Million)
Table 55. Ncardia Recent Development
Table 56. Sumitomo Dainippon Pharma Company Details
Table 57. Sumitomo Dainippon Pharma Business Overview
Table 58. Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Product
Table 59. Sumitomo Dainippon Pharma Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025) & (US$ Million)
Table 60. Sumitomo Dainippon Pharma Recent Development
Table 61. Astellas Pharma Inc Company Details
Table 62. Astellas Pharma Inc Business Overview
Table 63. Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Product
Table 64. Astellas Pharma Inc Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025) & (US$ Million)
Table 65. Astellas Pharma Inc Recent Development
Table 66. Fate Therapeutics, Inc Company Details
Table 67. Fate Therapeutics, Inc Business Overview
Table 68. Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Product
Table 69. Fate Therapeutics, Inc Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025) & (US$ Million)
Table 70. Fate Therapeutics, Inc Recent Development
Table 71. Pluricell Biotech Company Details
Table 72. Pluricell Biotech Business Overview
Table 73. Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Product
Table 74. Pluricell Biotech Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025) & (US$ Million)
Table 75. Pluricell Biotech Recent Development
Table 76. Cell Inspire Biotechnology Company Details
Table 77. Cell Inspire Biotechnology Business Overview
Table 78. Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Product
Table 79. Cell Inspire Biotechnology Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025) & (US$ Million)
Table 80. Cell Inspire Biotechnology Recent Development
Table 81. ReproCELL Company Details
Table 82. ReproCELL Business Overview
Table 83. ReproCELL Induced Pluripotent Stem Cells (iPSCs) Product
Table 84. ReproCELL Revenue in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025) & (US$ Million)
Table 85. ReproCELL Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
Table 89. Authors List of This Report
List of Figures
Figure 1. Induced Pluripotent Stem Cells (iPSCs) Picture
Figure 2. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Type: 2024 VS 2031
Figure 4. Human iPSCs Features
Figure 5. Mouse iPSCs Features
Figure 6. Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Application: 2024 VS 2031
Figure 8. Academic Research Case Studies
Figure 9. Drug Development and Discovery Case Studies
Figure 10. Toxicity Screening Case Studies
Figure 11. Regenerative Medicine Case Studies
Figure 12. Others Case Studies
Figure 13. Induced Pluripotent Stem Cells (iPSCs) Report Years Considered
Figure 14. Global Induced Pluripotent Stem Cells (iPSCs) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Induced Pluripotent Stem Cells (iPSCs) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Region: 2024 VS 2031
Figure 17. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Players in 2024
Figure 18. Global Top Induced Pluripotent Stem Cells (iPSCs) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Induced Pluripotent Stem Cells (iPSCs) as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Induced Pluripotent Stem Cells (iPSCs) Revenue in 2024
Figure 20. North America Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Induced Pluripotent Stem Cells (iPSCs) Market Share by Country (2020-2031)
Figure 22. United States Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Induced Pluripotent Stem Cells (iPSCs) Market Share by Country (2020-2031)
Figure 26. Germany Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Induced Pluripotent Stem Cells (iPSCs) Market Share by Region (2020-2031)
Figure 34. China Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Induced Pluripotent Stem Cells (iPSCs) Market Share by Country (2020-2031)
Figure 42. Mexico Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Induced Pluripotent Stem Cells (iPSCs) Market Share by Country (2020-2031)
Figure 46. Turkey Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Induced Pluripotent Stem Cells (iPSCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Fujifilm Holding Corporation (CDI) Revenue Growth Rate in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
Figure 50. Ncardia Revenue Growth Rate in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
Figure 51. Sumitomo Dainippon Pharma Revenue Growth Rate in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
Figure 52. Astellas Pharma Inc Revenue Growth Rate in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
Figure 53. Fate Therapeutics, Inc Revenue Growth Rate in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
Figure 54. Pluricell Biotech Revenue Growth Rate in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
Figure 55. Cell Inspire Biotechnology Revenue Growth Rate in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
Figure 56. ReproCELL Revenue Growth Rate in Induced Pluripotent Stem Cells (iPSCs) Business (2020-2025)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
